title: Modulation of the atopy patch test: tacrolimus 0.1% compared with triamcinolone acetonide 0.1%.
abstract: BACKGROUND
  The atopy patch test (APT) is an in vivo model to study the induction of eczema by inhalant allergens in atopic dermatitis patients. We studied the effect of pretreatment with topical tacrolimus 0.1% on APT in nonlesional skin of patients with atopic dermatitis.
  
  
  METHODS
  Nonlesional skin of the back of patients with atopic dermatitis (n = 8) was treated once daily for 3 weeks with tacrolimus 0.1% ointment. Cetomacrogol ointment (placebo) was used as a negative control and triamcinolone acetonide 0.1% ointment as positive control. Twenty-four hours after the last APT application, samples were taken from the three treated areas (t = 0 and 24 h) for immunohistochemical analysis.
  
  
  RESULTS
  Pretreatment with tacrolimus ointment did not suppress nonlesional skin infiltrate, in contrast to triamcinolone acetonide. Furthermore, tacrolimus did not inhibit the induction of the APT macroscopically (t = 24 h). An equal influx of T cells, eosinophils, dendritic cells, CD64+ and Fc epsilon RI-positive cells was present compared with placebo. Only CD36+ and CD68-positive cells were inhibited compared with placebo. All cell types were significantly inhibited in triamcinolone acetonide-treated sites compared with placebo.
  
  
  CONCLUSIONS
  Pretreatment with tacrolimus 0.1% ointment does not inhibit the APT reaction in patients with atopic dermatitis.
authors.affiliation: Department of Dermatology/Allergology, University Medical Centre, Utrecht, the Netherlands.
authors.forename: J M
authors.initials: JM
authors.lastname: Oldhoff
authors.forename: E F
authors.initials: EF
authors.lastname: Knol
authors.forename: M
authors.initials: M
authors.lastname: Laaper-Ertmann
authors.forename: C A F M
authors.initials: CA
authors.lastname: Bruijnzeel-Koomen
authors.forename: M S
authors.initials: MS
authors.lastname: de Bruin-Weller
mesh_terms: D000328:Adult; D000485:Allergens / Q000009:adverse effects / Q000187:drug effects; D001706:Biopsy; D002592:Cetomacrogol / Q000008:administration & dosage; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology; D003876:Dermatitis, Atopic / Q000276:immunology; D004485:Eczema / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D010328:Patch Tests / Q000379:methods*; D011237:Predictive Value of Tests; D017452:Receptors, IgG / Q000187:drug effects / Q000276:immunology; D013501:Surface-Active Agents / Q000008:administration & dosage; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*
chemical_list: D000485:Allergens; D007166:Immunosuppressive Agents; D017452:Receptors, IgG; D013501:Surface-Active Agents; D002592:Cetomacrogol; D014222:Triamcinolone Acetonide; D016559:Tacrolimus